ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO857

A Biomarker of Collagen Type VI Formation Is Associated to Allograft Outcome in Kidney Transplant Recipients

Session Information

  • Transplantation: Basic
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1801 Transplantation: Basic

Authors

  • Genovese, Federica, Nordic Bioscience, Herlev, Denmark
  • Sparding, Nadja, Nordic Bioscience, Herlev, Denmark
  • Rasmussen, Daniel Guldager Kring, Nordic Bioscience, Herlev, Denmark
  • Karsdal, Morten Asser, Nordic Bioscience, Herlev, Denmark
  • Birn, Henrik, Department of Biomedicine and Department of Nephrology, Aarhus C, Denmark
  • Jespersen, Bente, Aarhus Universityhospital, Aarhus N, Denmark
  • Norregaard, Rikke, Aarhus University, AARHUS N, Denmark
Background

A careful evaluation of kidney transplant recipients is important for a successful allograft outcome. Non-invasive biomarkers are needed to predict immediate and long-term kidney function after transplantation.
Preliminary findings have identified PRO-C6, a non-invasive biomarker of collagen type VI formation related to burden of kidney fibrosis, as a good prognostic marker for kidney function loss and mortality in chronic kidney disease patients.

Methods

Here we evaluate the prognostic potential of PRO-C6 in kidney transplant recipient by measuring PRO-C6 in plasma of 219 patients before transplantation, and 1 day, 3 months and 12 months after transplantation, by means of an ELISA developed at Nordic Bioscience.

Results

Levels of the serum PRO-C6 decreased significantly from baseline (median, 95% CI: 50.7, 46.7-53.5) to day 1 (median, 95% CI: 34.8, 31.1-38.3) and further decreased at month 3 (median, 95% CI: 14.2, 12.7-14.5), but not significantly from month 3 to month 12 (median, 95% CI: 13.5, 12.7-14.5).
PRO-C6 correlated with plasma creatinine before transplantation (rho =0.43, p<0.0001), 1 day after rho for PRO-C6 vs plasma creatinine was 0.67, p<0.0001, at 3 months after rho for PRO-C6 vs measured GFR was -0.58, p<0.0001, and at 12 months after rho for PRO-C6 vs measured GFR was -0.57, p<0.0001.
PRO-C6 measured either before transplantation and at day 1 after transplantation could identify patients who required dialysis one week after transplantation (delayed graft function) (AUC: 0.679, p<0.0001; and AUC: 0.860, p<0.0001, respectively). PRO-C6 measured 1 day after transplantation identified patients who still required dialysis three months after transplantation (AUC: 0.789, p<0.0001). Plasma creatinine measured one day after transplantation did not have any prognostic ability to identify patients with no graft function after 3 months.
PRO-C6 measured 1 day after transplantation was also associated to the time needed to reach a 50% reduction in plasma creatinine after transplantation (HR per doubling of PRO-C6: 0.659 (0.548-0.792), p<0.0001).

Conclusion

PRO-C6 measured in plasma was associated with delayed graft function and no function at 3 months after transplantation and it can potentially be used to identify the patients at risk of graft function loss.

Funding

  • Commercial Support